Belite Bio, Inc. filings document foreign-issuer disclosures for a clinical-stage biopharmaceutical company developing tinlarebant for degenerative retinal diseases. Form 6-K reports furnish press releases on clinical-trial progress, FDA-related regulatory updates, financial results, annual-report availability, material agreements, shareholder matters, and capital-structure activity involving American Depositary Shares.
The company's Form 20-F reporting framework covers audited consolidated financial statements and public-company disclosure for BLTE as a foreign private issuer. Its filing record centers on STGD1, geographic atrophy in advanced dry AMD, tinlarebant development, financing activity, governance matters, and the incorporation of furnished reports into effective Securities Act registration statements.
Belite Bio Chief Scientific Officer Nathan L. Mata reported open-market sales of 1,000 American depositary shares on April 16, 2026. The trades were executed at prices within ranges from about $158.16 to $164.22 per share.
The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, which allows preset selling of shares over time. All transactions involved American depositary shares, each representing one ordinary share of Belite Bio.
Belite Bio’s Chief Scientific Officer, Nathan L. Mata, sold 1,000 American depositary shares in open‑market transactions on April 15, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, and were priced around $167–$171 per share. Following these trades, Mata directly holds 15,666 American depositary shares of Belite Bio.
BLTE filed a Form 144 notice proposing the sale of 16,666 American Depositary Shares (ADS). The ADS were issued on 04/10/2025 via a stock option exercise, and the filing lists J.P. Morgan Securities LLC as the broker-dealer with trading on NASDAQ. The filing date shown is 04/15/2026.
Belite Bio Chief Executive Officer Lin Yu-Hsin reported open-market sales of 9,200 American depositary shares (ADS) of Belite Bio, Inc. on April 9, 2026. The ADS were sold in multiple transactions at weighted average prices ranging from $180.00 to $183.00 per ADS.
The filing states that these sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025. After the transactions, Lin held 170,934 ADS directly. Each ADS represents one ordinary share of Belite Bio.
Belite Bio director Wan-Shan Chen sold 1,100 American depositary shares in an open-market transaction. The sale took place on April 9, 2026 at an average price of $180.4301 per ADS. After this sale, Chen directly holds 9,096 ADS. Each ADS represents one ordinary share of Belite Bio. The transaction was executed under a Rule 10b5-1 trading plan that Chen adopted on December 23, 2025, indicating the sale was pre-arranged rather than timed at discretion.
Belite Bio, Inc.'s Chief Financial Officer Hao-Yuan Chuang reported open-market sales of a total of 6,200 American depositary shares on April 9, 2026. The sales were executed in multiple trades at weighted average prices ranging from about $180.35 to $183.08, pursuant to a pre-established Rule 10b5-1 trading plan adopted on December 22, 2025. Following these transactions, Chuang directly holds 93,800 American depositary shares, which each represent one ordinary share of the company.
BLTE submitted a Form 144 notifying the proposed sale of American Depositary Shares (each representing one ordinary share). The filing lists multiple recent acquisitions via ESOP exercise and RSU vesting, including transactions of 42,811, 15,113, 7,909, 11,388, and two 20,000-share entries, dated through 11/03/2025.
BLTE submitted a Rule 144 notice to sell 100,000 American Depositary Shares. The filing lists the sale as tied to an ESOP exercise with an executed date of 03/20/2025 and a cash transaction date of 03/19/2025. The cover data shows numeric entries 39,339,960 and 17,873,000 with an associated date of 04/09/2026.
Belite Bio, Inc. submitted Form 144 entries that show exercises-and-hold of stock options resulting in 1,400 shares on 08/26/2024 and 8,796 shares on 02/26/2025. The filing lists Common Stock and identifies J.P. Morgan Securities LLC as a broker.
Belite Bio director Chen Wan-Shan reported a compensation-related stock option award. On 3/31/2026, Chen acquired options to purchase 13,796 ordinary shares at an exercise price of 0.4386 per share, expiring on 12/22/2030.
According to the disclosure, these options stem from a grant originally issued on 12/23/2020 that vests upon meeting specific performance criteria. One such criterion was achieved on 3/31/2026, causing 13,796 additional ordinary shares to vest under the option. This is not an open-market buy or sell but a performance-based equity award.